Asimov and AGC Biologics Agree to Develop New Viral Vector Production Approach

CDMO AGC Biologics signed a licensing agreement for Asimov’s off-the-shelf LV Edge Packaging cell line. AGC Biologics’ Cell and Gene Center of Excellence in Milan now offers a lentiviral packaging system that enables production from a single-plasmid transfection instead of the standard four-plasmid process, according to Alec Nielsen, co-founder and CEO at Asimov.

‍

Combining an engineered HEK293 cell line that contains inducible viral genes, software for transfer plasmid design, and ready-to-transfer processes, the LV Edge Packaging system minimizes GMP plasmid cost, process complexity, and supply chain risk, adds Nielsen.

‍

“By working with the experts at AGC Biologics, we’re confident that we can empower drug developers to unlock the next generation of cell and gene therapies,” he continues.

‍

“After careful evaluation of the LV Edge Packaging system at our AGC Milan site using clinically relevant genes of interest, we look forward to providing this best-in-class technology for customers around the globe,” says Luca Alberici, executive vice president, global cell & gene technologies, AGC Biologics.

‍

The post Asimov and AGC Biologics Agree to Develop New Viral Vector Production Approach appeared first on GEN - Genetic Engineering and Biotechnology News.